Edesa Biotech (EDSA) has released an update.
Edesa Biotech, a clinical-stage biopharmaceutical company, will be showcasing its progress and engaging with investors at the Bloom Burton & Co. Healthcare Investor Conference in Toronto. The company’s CEO will present on April 17, discussing Edesa’s advanced drug candidates, including treatments for ARDS, pulmonary fibrosis, vitiligo, and Allergic Contact Dermatitis. Edesa Biotech is actively developing innovative therapeutics for various immuno-inflammatory diseases, with multiple clinical trials underway.
For further insights into EDSA stock, check out TipRanks’ Stock Analysis page.
